The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | APOLO: induction chemo-IO with concurrent chemo-RT in stage III NSCLC
Gerry Hanna, MBBCh, PhD, MRCP, FRCR, FRANZCR, Trinity College Dublin, Dublin, Ireland, comments on the Phase II APOLO trial (NCT04776447), which investigated induction chemo-immunotherapy with atezolizumab followed by standard concurrent chemo-radiotherapy and maintenance atezolizumab in unresectable stage IIIA-IIIC non-small cell lung cancer (NSCLC). Promising outcomes were reported in patients receiving induction therapy, suggesting potential improvements over the regimen evaluated in the PACIFIC trial (NCT02125461). This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
